Survival Benefit from mTOR Inhibition in Lymphoma

Patients who received sirolimus after allogeneic stem-cell transplantation had longer overall and progression-free survival than did patients who did not receive sirolimus.

Sirolimus (Rapamune) is an immunosuppressive agent used for prevention of graft-versus-host disease (GVHD) after allogeneic stem-cell transplantation. Based on the antilymphoma activity of other mTOR inhibitors, this agent — an inhibitor of the mammalian target of rapamycin (mTOR) signaling pathway — has been postulated to improve outcomes for lymphoma patients undergoing transplantation.

To test this hypothesis, investigators performed a single-institution, retrospective review of 190 adult lymphoma patients who underwent myeloablative or reduced-intensity conditioning (RIC) allogeneic stem-cell transplantation. Of these patients, 51% had non-Hodgkin lymphoma, 29% had chronic lymphocytic leukemia/small lymphocytic lymphoma, and 20% had Hodg…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee